Drug intelligence / Profile preview

AI-306

Development stage: Preclinical
Lead developer: Apeximmune Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AI-306 is a first-in-class monoclonal antibody developed by Apeximmune Therapeutics targeting a novel myeloid-expressed immune suppressor. It is designed as an immune oncology therapeutic with potential application both as a single agent and in combination therapy. The drug aims to modulate the tumor microenvironment by inhibiting immune suppression mediated by myeloid cells, thereby enhancing anti-tumor immunity. AI-306 is part of Apeximmune’s proprietary pipeline focusing on novel immuno-oncology targets and represents an innovative approach in cancer immunotherapy.

Targets

AIM-103

Beyond the preview

Go deeper on AI-306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI-306.

Explore the full profile